Hims & Hers Health (NYSE:HIMS) is gearing up to launch an off-patent version of Novo Nordisk's (NVO) (OTCPK:NONOF) older GLP-1 weight loss therapy liraglutide in 2025, CEO of the telehealth platform ...

Hims Hers Health Inc (NYSE:HIMS) reported third-quarter earnings that surpassed analyst expectations and raised its full-year ...

Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy ...

While Trump spent much of his nearly two-hour speech in Michigan ’s Grand Rapids hurling insults and profanities at his ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Says trajectory in 2024 “nothing short of phenomenal.” Says business trajectory setting “robust foundation” for 2025.

Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...

Hims & Hers Health, Inc. ( (HIMS) ) has released its Q3 earnings. Here is a breakdown of the information Hims & Hers Health, Inc.

Ashby Kilgore was a bit apprehensive when she retired after 46 years in the public school system. “It was like, ‘What the ...

Hims & Hers Health raised its full-year outlook after it swung to a profit in the third quarter boosted by a tax benefit and consumer demand for weight-loss drugs.

The U.S. stock market experienced a slight downturn on Monday, with the S&P 500 index dipping approximately 0.3%. The Dow ...

People often share their weight loss journey on social media, and no one should be the judge of it, as it’s something ...